Time to read
1 minute
Read so far

Adocia files patent applications for short-acting hormones administered via pump for obesity

Thu, 05/27/2021 - 08:35
Posted in:

Adocia has announced that three patent applications have been filed for the treatment of metabolic diseases including obesity, NASH (Non-Alcoholic Steato-Hepatitis), type 2 diabetes and neurodegenerative disorders. These patents relate to combinations of short-acting hormones administered via pump. First preclinical results obtained in obese mice population by a combination of glucagon-exenatide (BioChaperone GluExe) show a weight loss of 25% versus 15% with exenatide alone after 14 days of treatment (2019 ADA - poster presentation, 7/11/2019). A second combination of pramlintide and exenatide (PramExe), currently in development, also presents promising properties. The pumps used are those already marketed for insulin therapy, and in particular patch-pumps, which are easy to use and suitable for this purpose. The user can adjust the maximal tolerable dose and therefore optimise the benefit/risk balance.

"We want to establish a new therapeutic paradigm for chronic diseases such as obesity, allowing patients greater control over their treatment,” explained Gérard Soula, Adocia’s CEO. "Our vision is to empower people by helping them to regain control of their illness, by enabling them to adjust doses in real time with the help of modern pumps and connected devices for better adherence to long-term treatments. This is where the future is heading: personalised medicine and patient empowerment.”

Adocia is offering a disruptive therapeutic approach by infusing short-acting hormones via a pump so that patients can easily and quickly adjust the doses administered, in contrast to the current way of thinking which is to extend the duration of action of hormones to offer weekly injections. One of the disadvantages of long-acting hormones is the impossibility to interrupt the side effects - particularly gastrointestinal - which can sometimes last several days after administration. Pharmaco-epidemiological studies on the use of once-weekly GLP-1 hormones in type 2 diabetes reveal that 48.0% of patients stop treatment after one year, while 73.2% stopped after two years.

Pump-infusion opens a number of perspectives:

  • The patient can gradually increase the dose as recommended when initiating these hormonal treatments
  • The continuous infusion allows patients to maintain weight loss effect without concentration peaks that could cause side effects
  • The patient can stop and start the treatment at the touch of a button; side effects decrease rapidly due to the short-acting hormones, treatment can be resumed quickly once these effects have subsided
  • The patient has the freedom for a ‘day-off’, to momentarily pause treatment for greater flexibility on professional or personal occasions, improving quality of life
  • Algorithm development and machine learning could also improve treatment efficacy and tolerance

“Our expertise on diabetes hormones and the potential of insulin pumps led us to expand applications to other chronic diseases,” commented Olivier Soula, Deputy CEO and Director of R&D at Adocia. "Our next objective is to establish clinical proof-of-concept with good tolerance and efficacy of PramExe administered via pump, while being well-accepted by people suffering from obesity."

PramExe is a fixed-ratio co-formulation of an amylin analog (pramlintide) and a GLP-1 receptor agonist (exenatide). Pramlintide and exenatide are two hormones marketed for the treatment of diabetes and have already demonstrated separately positive effects on weight loss and satiety. Adocia’s innovation lies in combining weight loss effects of these two compounds administered with a wearable pump. Adocia’s PramExe combination is ready to be clinical tested in humans.